<ul><li>Global biopharmaceutical company Gilead Sciences has signed a definitive agreement to acquire MiroBio, a UK-based clinical-stage biotechnology startup for a cash consideration of USD 405 million subject to regulatory conditions. The announcement was preceded by MiroBio's USD 97 million Series B funding round, in June 2022, to advance its programs into clinical trials. </ul>

• Post-acquisition, MiroBio will continue operations in the UK. Gilead will have access to MiroBio’s discovery platform, I-ReSToRE (REceptor Selection and Targeting to Reinstate immune Equilibrium), and the entire portfolio of drug candidates consisting of five targets to date. The pharma company aims to combine the I-ReSToRE platform with its existing R&D to treat autoimmune and inflammatory diseases and to expand its pipeline in the coming years.

• Gilead Sciences has developed medicines to treat diseases such as HIV, viral hepatitis, cancer, and inflammation. Based in California, the company operates in over 35 countries.

• MiroBio’s proprietary I-ReSToRE platform was designed to help discover and develop treatment strategies for autoimmune diseases, based on an atlas of receptor expressions and functions, antibody discovery processes, and advanced bioinformatics. The firm’s technology was built on more than 15 years of checkpoint agonism research at the University of Oxford.